close to approving another new drug for obesity

The FDA is getting close to approving another new drug for obesity...Meridia (sibutramine) from Knoll.

Meridia inhibits the reuptake of serotonin and norepinephrine. It's in the same class as the antidepressant Effexor (venlafaxine).

In fact, Meridia was originally developed for use as an antidepressant. The manufacturer switched gears when they noticed that it causes weight loss. The weight loss market is a lot less crowded than the antidepressant market.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote